. 2022 Jul 20;158(9):1073–1076. doi: 10.1001/jamadermatol.2022.2383

Table. Summary of Patient Demographics, Clinical Characteristics, and Histologic Findings of Cases From the Present Study and the Literature.

Patient sex/age, y	Clinical history	Reaction		Time from dose 1 to onset, d	Location of lesions	Vaccine adverse effects	Diagnosis	TCR	CD4:CD8	CD30	Therapy	Outcome	Follow-up time, mo
Patient sex/age, y	Clinical history	Dose 1	Dose 2	Time from dose 1 to onset, d	Location of lesions	Vaccine adverse effects	Diagnosis	TCR	CD4:CD8	CD30	Therapy	Outcome	Follow-up time, mo
Female/50s	Psoriasis, transverse myelitis	Multiple papules	Progressed	14	Trunk, extremities	None	PLEVA	–	2:1	+	DOX, TCS	NCR	12
Male/late teens	None	None	Multiple papules, progressive	23	Trunk, extremities	None	PLEVA	+	1:3	–	DOX, NBUVB, TCS	NCR	10
Female/70s	None	None	Single papule	22	Upper arm	Mild systemic symptoms	CLH	+	2:1	+	Surgical excision	CR	13
Male/50s	None	None	Single papule	28	Upper arm	Fatigue	CLH	+	3:1	+	Resolved with biopsy	CR	9
Male/50s	Multiple sclerosis	Multiple papules	Progressed	4	Trunk, extremities, palms	None	LyP type A	NA	NA	–	MTX	NCR; flare with COVID-19	7
Female/20s	None	None	Multiple papules, progressive	42	Trunk, extremities	None	LyP type A	NA	NA	+	MTX	NCR; flare with non-COVID-19 viral illness	9
Male/70s (Brumfiel et al,³ 2021)	PCALCL	Tumor	None	2	Axilla	None	CD30 LPD	+	NA	NA	None	NCR	NA
Female/60s (Mintoff et al,⁴ 2021)	None	None	Single papule	7	Upper arm	None	CLH	NA	NA	NA	NA	NA	NA

Abbreviations: CD30 LPD, CD30-positive lymphoproliferative disorder; CLH, cutaneous lymphoid hyperplasia; CR, complete remission; DOX, oral doxycycline; LyP, lymphomatoid papulosis; MTX, oral methotrexate; NA, not available; NBUVB, narrowband UVB light; NCR, near complete remission; PCALCL, primary cutaneous anaplastic large cell lymphoma; PLEVA, pityriasis lichenoides et varioliformis acuta; TCR, T-cell receptor (γ/β) gene rearrangement assay; TCS, topical corticosteroids.